Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials

Autor:	Adelaide A. Hebert, Carsten Flohr, H. Chih-ho Hong, Alan D. Irvine, Evangeline Pierce, Hany Elmaraghy, Sreekumar Pillai, Zach Dawson, Sherry Chen, Clara Armengol, Elaine Siegfried, Stephan Weidinger
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	Adolescents atopic dermatitis lebrikizumab efficacy quality of life Dermatology RL1-803
Zdroj:	Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Druh dokumentu:	article
ISSN:	09546634 1471-1753 0954-6634
DOI:	10.1080/09546634.2024.2324833
Popis:	AbstractBackground Lebrikizumab, a high-affinity monoclonal antibody targeting IL-13, previously demonstrated clinical efficacy in three randomized, double-blind, placebo-controlled Phase 3 trials that included adults and adolescents with moderate-to-severe atopic dermatitis (AD): ADvocate1, ADvocate2, and ADhere.Aim This subset analysis evaluated 16-week physician- and patient-reported outcomes of lebrikizumab in the adolescent patients enrolled in these three trials.Methods Eligible adolescents (≥12 to
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/b5ef1bb85af14e1fb68d15d4099d7b35 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF